Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07794579 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Name: A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity — clinical trial record (NCT07794579)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ATTAIN-NOW

StatusNot Yet Recruiting

PhasePhase 3

SponsorEli Lilly and Company

Started2026-09

View on ClinicalTrials.gov ↗

This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.

Trial Details

NCT Number	NCT07794579
Lead Sponsor	Eli Lilly and Company
Conditions	Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
Enrollment	2,001 participants
Start Date	2026-09
Primary Completion	2029-08 (estimated)
Study Completion	2030-09 (estimated)
Updated on ClinicalTrials.gov	2026-08-31